Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab

References

• Ciulla TA, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–64. doi:10.2337/diacare.26.9.2653.
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Wild RG, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi:10.2337/diacare.27.5.1047
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463–23467. doi:10.1074/jbc.274.33.23463
   PubMed Web of Science ®Google Scholar
• Glassman AR, Wells JA 3rd, Josic K, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201–1210. doi:10.1016/j.ophtha.2020.03.021
   PubMed Web of Science ®Google Scholar
• McCloskey CF, Mongan AM, Chetty S, McAteer DMJ, Quinn SM. Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: an Irish Retrospective Study. Ophthalmol Ther. 2018;7(1):173–183. doi:10.1007/s40123-018-0123-0
   PubMed Web of Science ®Google Scholar
• Klein KA, Cleary TS, Reichel E. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Int J Retina Vitreous. 2017;3:16. doi:10.1186/s40942-017-0064-0
   PubMedGoogle Scholar
• Calugaru D, Calugaru M. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. Am J Ophthalmol. 2016;168:290–291. doi:10.1016/j.ajo.2016.05.015
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142(6):961–969. doi:10.1016/j.ajo.2006.06.068
   PubMed Web of Science ®Google Scholar
• Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1):204–210. doi:10.1007/s11095-008-9718-9
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185. doi:10.1007/s10456-011-9249-6
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration. Ophthalmology. 2011;118(4):672–678. doi:10.1016/j.ophtha.2010.08.008
   PubMed Web of Science ®Google Scholar
• Liu K, Wang H, He W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2022;106(10):1436–1443. doi:10.1136/bjophthalmol-2020-318690
   PubMed Web of Science ®Google Scholar
• Campos Polo R, Rubio Sanchez C, Garcia Guisado DM, Diaz Luque MJ. Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. Clin Ophthalmol. 2018;12:99–104. doi:10.2147/OPTH.S154421
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979. doi:10.1001/archophthalmol.2012.393
   PubMed Web of Science ®Google Scholar
• Akbas YB, Alagoz C, Cakmak S, Demir G, Alagoz N, Artunay HO. Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: a comparative study. Therapeutic Adv Ophthalmol. 2023;15. doi:10.1177/25158414231195174
   Web of Science ®Google Scholar
• Ren F, Zhang X, Gong H, et al. Two different initial treatment regimens of Conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study. Photodiagnosis Photodyn Ther. 2023:44. doi:10.1016/j.pdpdt.2023.103745
   Web of Science ®Google Scholar
• Lee S-J, Kim M, Kim Y. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema. Indian J Ophthalmol. 2015;63(4). doi:10.4103/0301-4738.158069
   Web of Science ®Google Scholar
• Zou C, Han C, Zhao M, et al. Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis. Clin Proteomics. 2018;15(1). doi:10.1186/s12014-018-9187-z
   Google Scholar
• Gonzalez VH, Campbell J, Holekamp NM, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: analysis of Protocol I Data. Am J Ophthalmol. 2016;172:72–79. doi:10.1016/j.ajo.2016.09.012
   PubMed Web of Science ®Google Scholar
• Ibrahim WS, Eldaly ZH, Saleh MG, Rateb MF, Aldoghaimy AH. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs. Korean J Ophthalmol. 2019;33(2):122–130. doi:10.3341/kjo.2018.0037
   PubMedGoogle Scholar
• Nawar AE, Wasfy T, Shafik HM. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection. BMC Ophthalmol. 2022;22(1):287. doi:10.1186/s12886-022-02503-x
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–733. doi:10.1167/iovs.04-0601
   PubMed Web of Science ®Google Scholar
• Ternant PG. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(Suppl 1):S37–47. doi:10.1517/14712598.5.1.s37
   PubMedGoogle Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2017;9(1):15–32. doi:10.1007/s13238-017-0408-4
   PubMed Web of Science ®Google Scholar
• Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res. 2012;97(1):154–159. doi:10.1016/j.exer.2011.09.002
   PubMed Web of Science ®Google Scholar
• Du PH, Wu Q, Zhu M, et al. Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept. Mol Vis. 2015;21:185–193.
   PubMed Web of Science ®Google Scholar
• Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21–23. doi:10.1136/bjo.2011.203893
   PubMed Web of Science ®Google Scholar